Epitalon / dosage
Epitalon dosage in the research record: doses, routes, and half-life
The doses and routes used in published studies, the cycled-administration pattern, and why no human pharmacokinetic half-life exists.
Before the details
This page describes Epitalon dosage only as it appears in published research — what was given, to which species, by which route, in which study. It is not a protocol, and it contains no recommendation for any person. In short: the rodent lifespan work used roughly a microgram per mouse, injected under the skin, for five days a month rather than every day; cell studies used concentrations in the microgram-per-milliliter range; and the human studies used parenteral courses over short cycles. No one has measured how long Epitalon lasts in a human bloodstream, so the often-repeated "a few minutes" figure is an educated guess from peptide chemistry, not a number from an Epitalon study. Wherever you see a dose below, read it as "this is what a study did," never as "this is what to take."
Epitalon dosage
Epitalon dosage in the research record means the doses used in animal and cell studies. The most-cited rodent regimen comes from the SHR-mouse lifespan study: 1.0 ug/mouse subcutaneously (roughly 30-40 ug/kg), given five consecutive days per month from three months of age [3]. Lower-dose rodent carcinogenesis schedules used 0.1 ug/mouse subcutaneously, and a rat colon-carcinogenesis model used a 1 ug subcutaneous course [12]. In vitro, the 2025 human cell-line telomere studies used 0.1-1 ug/mL in the culture medium [8]; the original human-fibroblast telomerase work added the peptide to culture medium at a concentration the abstract did not specify [1]. The shared feature across the rodent work is intermittent, cycled dosing rather than continuous exposure.
Routes studied
Subcutaneous injection is the predominant route in both the rodent and the reported human work [3]. Cell and oocyte studies add the peptide directly to culture medium [8]. One rat study delivered the peptide intranasally to examine neocortex neuron activity, and the Russian clinical and observational studies used parenteral courses over 10-20 day cycles [2]. The route table on this page, drawn from the studies, pairs each route with the model it was used in; none of it describes administration to a person outside a research setting.
Epitalon half life
No formal pharmacokinetic half-life study has been published for Epitalon in humans. As an unmodified linear tetrapeptide, it is expected to undergo rapid proteolytic degradation in plasma, consistent with short-peptide half-lives that are generally measured in minutes — but this is an inference from peptide chemistry, not a measured Epitalon value [4]. The practical consequence researchers cite for the short presumed half-life is that any systemic effect would be brief, which is part of the rationale offered for the cycled dosing pattern. Until a human pharmacokinetic study is run, the Epitalon half life should be treated as unknown rather than as the "few minutes" figure that circulates.
Why researchers cycle rather than dose continuously
The rodent studies consistently used short monthly courses — five days on, the rest of the month off — rather than daily administration [3]. The stated reasoning combines the presumed short half-life with the geroprotector framing, in which periodic pulses are proposed to normalize an age-related axis rather than to maintain a continuous blood level. This cycled pattern is a feature of the study designs; it is not a dosing instruction, and the published record does not establish an optimal interval for any species, let alone for humans.
Handling and stability in research practice
In research handling, lyophilized peptide is typically stored at -20 C; reconstituted solution in bacteriostatic water is refrigerated at 2-8 C and used within a few weeks, since repeated freeze-thaw cycling degrades short peptides. These are general research-handling conventions, not manufacturer directions or clinical guidance. No human clinical dosing exists to standardize against: no Phase II/III randomized placebo-controlled trial for Epitalon is registered, and the published human courses used Russian parenteral schedules that differ from FDA/EMA reporting standards [2].